Clinical trial
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma…
NCT00294632 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00294632 |
|---|---|
| Title | Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma |
| Official title | Lenalidomide and Rituximab Treatment of Relapsed Mantle Cell Lymphoma and Diffuse Large B-Cell Non-Hodgkin's Lymphoma, Transformed Large Cell Lymphoma, and/or Grade 3 Follicular Lymphoma (Follicular Cleaved Large Cell Lymphoma or Follicular Non-Cleaved Large Cell Lymphoma (RV-LYM-PI-0056) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Lenalidomide, Rituximab |
| Enrollment | 54 |
| Start date | Feb 1, 2006 |
| Primary completion | Feb 1, 2016 |
| Completion | Feb 1, 2016 |
| First posted | Feb 22, 2006 |
| Last update posted | Feb 24, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: